Dose Selection in Phase I Studies: Why We Should Always Go for the Top
- 1 April 2008
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (10), 1576-1578
- https://doi.org/10.1200/jco.2007.15.5192
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2008
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2008
- Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic DataJournal of Clinical Oncology, 2008
- RAD001 Inhibits Human Ovarian Cancer Cell Proliferation, Enhances Cisplatin-Induced Apoptosis, and Prolongs Survival in an Ovarian Cancer ModelClinical Cancer Research, 2007
- The Mammalian Target of Rapamycin Signaling Pathway: Twists and Turns in the Road to Cancer TherapyClinical Cancer Research, 2007
- Targeting HER2 in Prostate Cancer: Where to Next?Journal of Clinical Oncology, 2007
- Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mgEuropean Journal Of Cancer, 2005
- Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell CarcinomaJournal of Clinical Oncology, 2004
- Antitumor Efficacy of Intermittent Treatment Schedules with the Rapamycin Derivative RAD001 Correlates with Prolonged Inactivation of Ribosomal Protein S6 Kinase 1 in Peripheral Blood Mononuclear CellsCancer Research, 2004
- Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I studyThe Lancet, 2001